Ryvu Therapeutics S.A. (RVU.WA)
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
14.74-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-50.9%
The outlook
Ryvu Therapeutics S.A. currently reads as neutral based on buy — 2.2 avg of 5 analysts, below its 50- & 200-day averages, 6% of the way from its 52-week low to high, avg target +128% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 2.2 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Price targetAvg target +128% vs current price
Analyst price target
~12-month · 5 analysts33.62average target+128.1% vs now
Now 14.74
Low 17.00High 49.10
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$340.8M
52-wk high
31.90
52-wk low
13.64
50-day avg
15.18
200-day avg
22.67
Trailing P/E
—